'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed

Amber Tong

In a field now defined by Biogen’s Aduhelm — and the storm of controversy around it — what constitutes “industry-leading” data for an Alzheimer’s drug?

Alzheon, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Very over sol­d': Biotech brags about PhII Alzheimer's da­ta, but ex­perts are un­der­whelmed

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed